Analysts Set Evotec AG (NASDAQ:EVO) Price Target at $7.00

Evotec AG (NASDAQ:EVO) has been given an average recommendation of “Hold” by the five research firms that are covering the stock, MarketBeat reports. One research analyst has rated the stock with a sell rating, one has given a hold rating and three have assigned a buy rating to the company. The average 12 month price objective among brokerages that have covered the stock in the last year is $7.00.

Several brokerages recently commented on EVO. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Evotec in a report on Monday, December 29th. Wall Street Zen raised Evotec from a “sell” rating to a “hold” rating in a report on Saturday, January 10th. Finally, Berenberg Bank began coverage on Evotec in a research report on Tuesday, February 3rd. They issued a “buy” rating on the stock.

Institutional Trading of Evotec

Several large investors have recently added to or reduced their stakes in the business. Marshall Wace LLP purchased a new stake in Evotec during the fourth quarter valued at approximately $40,000. Valeo Financial Advisors LLC purchased a new position in shares of Evotec during the 2nd quarter worth $43,000. BNP Paribas Financial Markets grew its position in shares of Evotec by 62.2% during the 2nd quarter. BNP Paribas Financial Markets now owns 12,000 shares of the company’s stock valued at $50,000 after acquiring an additional 4,600 shares during the period. Thrivent Financial for Lutherans bought a new stake in shares of Evotec during the 3rd quarter valued at $53,000. Finally, Bank of America Corp DE increased its stake in shares of Evotec by 262.5% in the 4th quarter. Bank of America Corp DE now owns 12,828 shares of the company’s stock worth $53,000 after purchasing an additional 9,289 shares in the last quarter. 5.81% of the stock is currently owned by institutional investors.

Evotec Trading Down 1.6%

NASDAQ:EVO opened at $2.42 on Wednesday. The company has a quick ratio of 2.03, a current ratio of 2.12 and a debt-to-equity ratio of 0.48. The company has a 50 day simple moving average of $3.19 and a two-hundred day simple moving average of $3.37. Evotec has a 12 month low of $2.31 and a 12 month high of $4.80.

Evotec Company Profile

Evotec SE (NASDAQ:EVO) is a global biotechnology company headquartered in Hamburg, Germany, specializing in drug discovery and development partnerships. The company leverages its integrated discovery platforms to support pharmaceutical and biotech clients in advancing novel therapies from target identification through preclinical development.

Evotec’s service offering encompasses high-throughput screening, bioanalytics, combinatorial chemistry, structural biology, pharmacology, and computational drug design.